

CURRICULUM VITAE

PERSONAL DATA

Name: Linda Stein Gold, M.D.

Office Address: 6530 Farmington Road
West Bloomfield, MI 48322
(248) 661-8764

Research Office: Henry Ford Medical Center-New Center One
Department of Dermatology
3031 West Grand Boulevard, Suite 800
Detroit, MI 48202

Born: Pittsburgh, PA

EDUCATION

Residency: Department of Dermatology, Henry Ford Hospital
Detroit, MI 1990-1993
Honors: Chief Resident 1993
Resident Basic Science Research Award, T-cell cytokines in LE
Resident Research Scholarship, World Congress of Dermatology
Pseudolymphoma: A Diagnostic Algorithm, 1992

Internship: Department of Internal Medicine,
Hospital of the University of Pennsylvania
Philadelphia, PA 1989-1990

Medical School: University of Pennsylvania School of Medicine
Philadelphia, PA 1985-1989

Undergraduate: The Wharton School, University of Pennsylvania
Philadelphia, PA, B.S. Economics 1981-1985
Honors: Magna Cum Laude

Professional: Physician Leadership Academy
Henry Ford Hospital
Detroit, MI 2012

MEDICAL LICENSE: Michigan

ACADEMIC APPOINTMENTS

October 2002- Present Director Dermatology Clinical Research, Henry Ford Health System.
Detroit, MI

May 1994- Present Division Head of Dermatology, Henry Ford Health System
West Bloomfield, MI
Supervise three staff physicians and seven support staff

May 1993-Sept. 2002 Associate Director Dermatology Research, Henry Ford Health System,
Detroit, MI

July 1993-April 1994 Senior Staff Physician, Henry Ford Health System, West Bloomfield MI

CLINICAL RESEARCH

- A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Patients with Moderate to Severe Chronic Plaque-Type **Psoriasis**” (CAIN457A2211E1). (2010-2013)
- Galderma, ACNE 2013-2014 **A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP VEHICLE AND ACTIVE CONTROLLED STUDY TO COMPARE THE EFFICACY AND SAFETY OF CD0271 0.3% / CD1579 2.5% TOPICAL GEL VERSUS TOPICAL GEL VEHICLE IN SUBJECTS WITH ACNE VULGARIS**
- LEO, AK, on hold 2013-2014
Safety and efficacy of escalating doses of two LEO 43204 formulations applied once daily for two consecutive days on full face or approximately 250 cm² (40 in²) on the chest in subject with actinic keratosis.
- CuTech-Promius 2013-2014
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of Betamethasone Dipropionate Spray 0.05% in the Treatment of Moderate Plaque Psoriasis
Therapeutics, Watson, Hyperhidrosis 2013-2014
A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of An Anticholinergic Agent for the Treatment of Primary Axillary Hyperhidrosis
- Therapeutics, Psoriasis 2013-2014
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP COMPARISON OF HALOBETASOL PROPIONATE LOTION 0.05% VERSUS VEHICLE LOTION IN SUBJECTS WITH PLAQUE PSORIASIS
- Tolmar, Rosacea 2013-2014
TOL2665A: A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing TOLMAR Azelaic Acid Gel, 15% to Reference Listed Drug in the Treatment of Rosacea
- A Sequential Treatment Regimen of Cryotherapy and Picato (Ingenol Mebutate) gel, 0.015% Field Therapy Compared to Cryotherapy Alone for the Treatment of **Actinic Keratosis** on the Face and Scalp (2012-2013)
- A Parallel-Group, Vehicle-Controlled, Randomized, Double-Blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects with **Seborrheic Dermatitis** (2012-2013)
- Safety and Efficacy of Luliconazole Solution, 10% with Two Dosing Regimens in Distal **Subungual Onychomycosis** of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2b/3 Study (2012-2013)
- A Multicenter, randomized, double-blind, placebo-controlled, Phase 3 study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized **subcutaneous fat in the submental area** (2012-2013)
- A Multicenter, Randomized, Double-Blind, Four-Week, Bilateral Study of the Safety and Efficacy of Two Concentrations of AN2728 Ointment Administered Once or Twice a Day in Adolescents with **Atopic Dermatitis** (2012-2013)
- A Phase 3 Randomized, Double-Blind, 12 Week Vehicle-Controlled, Parallel- Group Study Assessing the Efficacy and Safety of CD5024 1% Cream Versus Vehicle Versus Cream in Subjects with **Papulopustular Rosacea** , Followed by a 40-Week Investigator-Blinded Extension Comparing the Long-Term Safety of CD5024 1% Cream Versus Azelaic Acid 15% Gel (2012-2013)
- A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd. Aclapalene - Benzoyl Peroxide Topical Gel 0.1%/2.5% to Epiduo® Topical Gel (Aciapalene - Benzoyl Peroxide Gel 0.1%/2.5%), and Both Active Treatments to a Vehicle Control in the Treatment of **Acne Vulgaris** (2011-2012)
- A Double-blind, Randomized, Parallel-design, Vehicle-controlled, Multicenter Trial Comparing Generic to Innovator Clindamycin, 1% and Benzoyl Peroxide, 5% Topical Gel and Both Active Treatments to a Vehicle Control in the Treatment of **Acne Vulgaris**. (2011-2012)

- Calcipotriol plus betamethasone dipropionate topical suspension compared to betamethasone dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension vehicle and the topical suspension vehicle alone in **psoriasis vulgaris**. (2010-2011)
- A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in the Treatment of Moderate, Plaque-Type **Scalp and Body Psoriasis**. (2010-11)
- A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects with **Tinea Pedis**. (2011)
- A Phase IV, Open-Label Study Evaluating the Use of Solodyn® (Minocycline HCL Extended-Release Tablets), Ziana® and Triaz® Foaming Cloths as Combination **Acne** Therapy for Potential Isotretinoin Candidates. (2010-2011)
- A Multi-Center, Randomized, Vehicle-Controlled, Double-Blind, Study to Evaluate the Safety and Efficacy of Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Administered Once Daily for the Treatment of Subjects 9 to 11 Years of Age with **Acne Vulgaris** (2010-2011)
- A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects with **Acne Vulgaris**.(2009-2010)
- A randomized, double-blind, placebo controlled, multicenter regimen finding study of subcutaneously administered AIN457, assessing Psoriasis Area and Severity Index (PASI) response in patients with moderate to severe **chronic plaque-type psoriasis**. (2009-2010)
- A 12 month, long-term follow-up study of patients with **actinic keratosis** on non-head areas (trunk and extremities) who have completed Day 57 in study PEP005-020 (2009-2010)
- A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Diclofenac Sodium Gel, 3%and Solaraze™ (Diclofenac Sodium) Gel, 3% and Compare Both Active Treatments to a Vehicle Control in the Treatment of **Actinic Keratosis** (2009)
- A Phase II, Randomized, Double-Blind, Vehicle-Controlled Cross-Over Study to Determine the Anti-Pruritic Efficacy, Safety and Local Dermal Toleration of SRD174 Cream in Subjects with **Atopic Dermatitis**. (2009)
- A multi-center, open-label study to evaluate the safety and efficacy of PEP005 (ingenol mebutate) Gel, 0.05% in patients with **actinic keratoses** on non-head locations (trunk and extremities) (2009)
- A multi-center, Randomized, parallel group, double-blind, vehicle-controlled study to Evaluate the efficacy and safety of PEP005 (ingenol mebutate) Gel, 0.05% in patients with **actinic keratoses** on non-head locations(2008-2009)
- A **phase 2**, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in subjects with **distal subungual onychomycosis** (2008-2010)
- Efficacy and Safety comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Vehicle Gel as a 6-month **Acne** Maintenance Treatment (2008-2009)
- Efficacy and Safety comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel associated with Doxycycline Hyclate versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel associated with Doxycycline Hyclate 100 mg Tablets in the Treatment of **Severe Acne Vulgaris** (2008-2009)
- A Phase 4, Open-Label Study to Assess the Long-Term Safety of Extina (Ketoconazole) Foam, 2% in the Treatment of **Seborrheic Dermatitis** (2008-2009)
- A Phase 3 Multicenter, Randomized, Double-Blind, Active and Vehicle-Controlled Study of the Safety and Efficacy of Clindamycin- Tretinoin Gel Versus Clindamycin Gel Versus Tretinoin Gel Versus Vehicle Gel in Subjects with **Acne Vulgaris**(2008)
- A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in the Treatment of Subjects with **Moderate to Severe Chronic Plaque Psoriasis**(2008)
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects with Moderate to Severe **Chronic Plaque Psoriasis** (Sub-I) (2008)

- A Multi-Center, Double-Blind, vehicle-Controlled Study Comparing Imiquimod Cream 5% (Apotex, Inc.) to ALDARA™ Cream 5% (3M Pharmaceuticals, U.S.) and ALDARA™ Cream 5% (3M Pharmaceuticals, Canada) in the Treatment of **Actinic Keratosis** (2008)
- A Phase 2, Multi-Center, Evaluator- Blind, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of IDP-115 in the Treatment of **Rosacea** (2008)
- A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the Efficacy and Safety of Adapalene Lotion, 0.1% Compared With Vehicle Lotion in Subjects with **Acne Vulgaris** (2008)
- A Randomized, Double-blind Study to Evaluate the Efficacy of a New Oral, Low Dose Formulation of Doxycycline as Compared to Placebo in the Treatment of Moderate to Severe Inflammatory Facial **Acne Vulgaris** (2008)
- A phase 4 comparison between clobetasol propionate (Clobex®) spray and clobetasol propionate ointment with regard to efficacy, safety, subject satisfaction and duration of response in moderate to severe stable **plaque psoriasis**
- A phase 4, comparison of adapalene gel, tazarotene cream, vs. adapalene gel 6-week treatment switched to tazarotene cream, 6-wk treatment in patients with **acne vulgaris** 2006-7
- A phase 3, randomized, double blind parallel group study to demonstrate the efficacy and safety of clindamycin/benzoyl peroxide gel compared to clindamycin gel, benzoyl peroxide gel, and vehicle gel in subjects with **acne vulgaris**. 2006-7
- A phase 3 randomized, double blind study of 3 doses PEP-005 compared to vehicle gel in the treatment of **actinic keratoses** 2006-7
 - A phase 3, randomized, double blind, vehicle controlled, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail **Onychomycosis** 2007
 - Dose effect study of incyclinide in **rosacea** 2007
 - A phase 3 randomized, double blind, parallel group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide gel compared with adapalene gel, benzoyl peroxide gel, and gel vehicle in subjects with **acne vulgaris** 2006-7
 - A phase 3, long term, open label study to evaluate the safety of twice daily tacrolimus cream-B 0.1% in the treatment of **psoriasis** 2005-2007
 - A 10 year prospective study to assess safety of tacrolimus ointment for **atopic dermatitis** 2005
 - A randomized, double-blind, vehicle-controlled study of the safety and efficacy of ketoconazole foam, 2%, versus Teva® (ketoconazole) 2% cream in the treatment of **seborrheic dermatitis** 2005-6
 - A multi-center study to assess the impact of topical corticosteroids on the safety and efficacy of Protopic® (tacrolimus) ointment in the short-term treatment of atopic dermatitis and to assess Protopic in the long-term management of **atopic dermatitis** 2005-6
 - A multi-center, phase 3, randomized, double-blind, clinical trial to compare the safety and efficacy of Clin-RA Gel vs. clindamycin phosphate 1.2% gel in the treatment of **acne vulgaris**
 - A phase 4, double-blind, multicenter, randomized, vehicle-controlled, cross-over study to further evaluate the risk of hematological adverse events in G6PD-deficient subjects with **acne vulgaris** treated with ACZONE™ (dapsone) gel, 5% 2005-6
 - A randomized, double-blind, vehicle-controlled study to evaluate the efficacy of Dovobet® (calcipotriene, 0.005% and betamethasone, 0.05%) ointment compared to ointment vehicle in subjects receiving Enbrel® (etanercept) for the treatment of **psoriasis vulgaris** 2006
 - A comparison of Differin® gel, 0.1% vs. Tazorac® cream, 0.1% vs. Differin® gel, 0.1% 6-week treatment switched to Tazorac® Cream, 0.1% 6-week treatment in patients with **acne vulgaris**
 - A phase 3, long-term, open label study to evaluate the safety of once daily 0.3% tacrolimus gel in the treatment of **psoriasis**. 2003-2004.
 - Phase III vehicle-controlled, double-blind study to assess the safety and efficacy of Imiquimod cream,5%, for the treatment of **molluscum contagiosum** in pediatric subjects. 2004.
 - An open-label 18month safety study of Carac cream for the treatment of **actinic keratoses**. 2004.

- A phase III, randomized, double-blind, parallel group, multicenter, efficacy and safety study of 12% ciclopirox nail lacquer versus vehicle for the treatment of **onychomycosis**. 2004.
- A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of Desonide Foam, 0.05% in the Treatment of Adolescent and Pediatric Subjects with Mild to Moderate **Atopic Dermatitis** 2004
- A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Generic Ciclopirox Gel 0.77% to Loprox® Gel (ciclopirox) 0.77% and Both Active Treatments to a Vehicle Control in the Treatment of **Tinea Pedis (Athlete's Foot)** 2004
- A double –blind, randomized, vehicle-controlled trial to determine the efficacy and safety of hydrocortisone butyrate 0.1% lotion in the treatment of **atopic dermatitis** or **eczema** in adults. 2003-2004.
- A randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of three dose levels of rosiglitazone maleate in the treatment of **chronic plaque psoriasis**. 2003-2004.
- A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter, multidose study of subcutaneously administered anti-CD-11a antibody in adults with **moderate to severe plaque psoriasis** who are candidates for systemic therapy. 2002.
- A multi-center, double-blind, randomized, placebo-controlled study of the safety and efficacy of 12 weeks treatment with tazarotene 4.5 capsules patients with **moderate to very severe plaque psoriasis**.2002-2003.
- A multi-center, open-label study of tazarotene 4.5mg capsules for 12 weeks followed by 12-week post treatment follow-up in **psoriasis** patients who have no change or an increase in their overall lesional assessment after 12 weeks of treatment in a study of oral tazarotene 4.5mg versus placebo. 2003.
- A phase III, multicenter, randomized, double-blind, active- and vehicle-controlled study of the safety and efficacy of Velac gel for the treatment of **acne vulgaris**. 2003-2004.
- A randomized double-blind, double-dummy, placebo-controlled study of the safety and efficacy of 2% ketoconazole foam VS Nizoral (ketoconazole) 2% cream in the treatment of **seborrheic dermatitis**. 2002.
- A randomized, partially double-blinded, multicenter trial comparing the efficacy and safety of Diflucan (fluconazole) for 3 weeks VS Diflucan for 6 weeks VS Grifulvan V (griseofulvin) for 6 weeks given once daily to pediatric patients with **tinea capitis**. 2002.
- Evaluation of the efficacy and safety of twice daily application of Calcitriol 3ug/g ointment and its vehicle in the treatment of chronic plaque **psoriasis**. 2002.
- An observational study of the recurrence and re-treatment of **actinic keratosis** after treatment with Carac and Effudex. 2001.
- A phase II, randomized parallel group, efficacy and safety study of BMS-234303 1%,2% VS vehicle QD (double-blinded), minoxidil 5% VS its vehicle BID (double-blinded) and BMS-234303 1% and 2% VS minoxidil 5% BID (single-blinded) in adult males with **androgenetic alopecia**.2000.
- Clinical safety trial of “daily-use” PENIPRO lotion in long term conditions. 2001.
- A multi-center, double-blind, randomized, placebo-controlled study of the safety and efficacy of 12 weeks of treatment with tazarotene 4.5 mg capsules once daily followed by a 12 week post-treatment follow-up period in patients with **moderate to very severe psoriasis**. 2001-2002.
- A 12 week, multicenter, double-blind, randomized, parallel-design study of dapsone topical gel VS vehicle in the treatment of **acne**. 2001.
- A randomized, double-blind, placebo-controlled study of the safety and efficacy of OLUX (clobetasol propionate) foam 0.05% in the treatment of mild to moderate plaque **psoriasis** of the nonscalp. 2001.
- A double-blind, randomized, parallel-group, placebo-controlled, multi-center study to evaluate the safety and bioequivalence of ketoconazole shampoo 2% VS Nizoral (ketoconazole) 2% shampoo in patients with **tinea versicolor**. 2001.
- A randomized, double-blind study of Protopic (tacrolimus) 0.03% ointment VS vehicle in adult patients with mild to moderate **atopic dermatitis**. 2001.

- Long-term safety assessment of Helioblock SX cream in patients with **polymorphous light eruption**. 2001.
- A double-blind, randomized, parallel-group, placebo-controlled, multi-center study to evaluate the safety and efficacy of ASM981 (pimecrolimus) cream 1% BID VS standard care in the management of mild to severe **atopic dermatitis** in children 3 months to 11 years. 2001.
- A double-blind, placebo controlled multi-center study to determine the effect of finasteride in men with **advanced male pattern hair loss**. 2000-2002.
- A double-blind, randomized, placebo-controlled, multi-center study to assess the effects of norethindrone acetate and ethinyl estradiol in the control of **age related skin changes in** postmenopausal women. 2000.
- A double-blind, randomized, parallel-group, placebo-controlled, multi-center comparison of Tazorac (tazarotene) 0.1% gel and calcipotriol 0.0005% ointment in the maintenance of treatment success in subjects with plaque **psoriasis**. 2000.
- A double-blind, randomized, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and tolerability of finasteride 1 mg. On hair loss in men aged 41-60 with **androgenetic alopecia**. 1999-2002.
- A double-blind, randomized, parallel-group, placebo-controlled, multi-center multi-dose study to evaluate the safety and efficacy of SQ administered anti-CD11a in adults with moderate to severe **psoriasis**. 2000-2001.
- A double-blind, randomized, placebo-controlled, multi-center comparison/combo study with L-762943 and oral minocycline to evaluate their effects in young men **with moderate to severe acne**. 1999-2000.
- A double-blind, randomized, parallel-group, placebo-controlled, multi-center study to evaluate the safety and efficacy of Luxiq in the treatment of nonscalp **psoriasis**. 2000.
- A double-blind, randomized, parallel-group, placebo-controlled, multi-center study to evaluate the effect of finasteride on hair loss in men with **androgenetic alopecia**. 1994-2000.
- A double-blind, randomized, parallel-group, placebo-controlled, multi-center study to evaluate the safety and efficacy of tazarotene cream 0.1% QD for patients with **acne**. 1999-2000.
- A multi-center, open-label evaluation of terbinafine therapy in the treatment of **onychomycosis** of the toenails in elderly patients. 1996-1998.
- A double-blind, randomized, parallel-group, placebo-controlled, multi-center study to evaluate the safety and efficacy of Estrostep in the treatment of **acne vulgaris**. 1998-1999.
- Randomized, double-blind, placebo-controlled study of itraconazole capsules for intermittent therapy for onychomycosis of the toenails. 1994-1995.

PUBLICATIONS

Rigel DS, Stein Gold LF, The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol . 2013 Jan;68(1Suppl)S20-7.

Tan J, Stein Gold L, Schlessinger J, et al. Short-term combination therapy and long-term relapse prevention in the treatment of severe acne vulgaris. J Drugs Dermatol. 2012 Feb;11(2):174-80.

Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, **Stein Gold L**, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr; National Psoriasis Foundation Medical Board. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012 Jan;148(1):95-102. doi: 10.1001/archdermatol.2011.1410.

Tan J, Wolfe B, Weiss J, **Stein-Gold L**, et al., Acne severity grading: determining essential clinical components and features using a Delphi consensus J Am Acad Dermatol. 2012 Aug;67(2):187-93.

Stein Gold L. Top Accessed Article: Successful treatment of Trichophyton rubrum Nail Bed (Distal Subungual) Onychomycosis. Arch Dermatol. 2011;147(6)716

Stein Gold L, Cruz A, Eichenfield L, Tan J, Jorizzo J, Kerrouche N, Dhuin J-C. Effective and Safe Combination Therapy for Severe Acne Vulgaris: A Randomized, Vehicle-Controlled, Double-blind Study of Adapalene 0.1%–Benzoyl Peroxide 2.5% Fixed-Dose Combination Gel With Doxycycline Hyclate 100 mg. *Cutis*. 2010;85:94-104.

Stein Gold L. Top-Accessed Article: Acne Vulgaris. *Arch Dermatol*. 2010;146(6):604

Stein Gold L. Fixed-Combination Products in the Management of Acne Vulgaris. *Cutis*. 2010;85:160-167.

Stein Gold L. Calcitriol Ointment: Optimizing psoriasis therapy. *J Drugs Dermatology* 2009; 8:S 23-27.

Del Rosso J, Baldwin H, Keri J, Mancini A, Stein Gold L, Webster G. Current Approach to Acne Management: A Community-Based Analysis. *Cutis* 2009;83(suppl 6):5-21.

Stein Gold L, Corvari L. The roles of safety and compliance in determining effectiveness of topical therapy for psoriasis. *Cutis*. 2007;79(1 Suppl 2):32-8.

Feldman SR, Gelfand JM, Stein Gold L, Jones SD. The role of topical therapy for patients with extensive psoriasis. *Cutis*. 2007;79(1 Suppl 2):18-31.

Stein LF: Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis, *J Am Acad Dermatol* 2005;53:S39-49.

Stein LF, Sherr A, et.al. Betamethasone Valerate Foam for Treatment of Nonscalp Psoriasis, *J Cutan Med Surg* 2001; 303-307.

Smith EB, Stein LF, et al: Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet. *Int J Dermatol* Nov;39(11):861-4, 2000.

Stein LF, Said G, Fivenson DP: T cell cytokines in Lupus Erythematosus: Aberrant IL2, IL-5 and IFN-g mRNA levels in skin lesions, *J Am Acad Dermatol* 36:191-7, 1997.

Stein LF, Lowe L, Fivenson DP: Coalescing violaceous plaques forming leonine facies, *Arch Dermatol* 130:1551, 1994.

Stein LF, Lowe, Fivenson DP: Making sense of Pseudolymphoma: An algorithmic approach. *Clin Res* 40:479A, 1992.

PRESENTATIONS

Frequent national and international lecturer on areas of psoriasis, alopecia, viral infections, atopic dermatitis and fungal infections at Grand Rounds and medical society meetings. Other meetings include:

Topical treatment of Acne, Skin Disease Education Foundation, Las Vegas 2010-2012.

State of the Art Topical Treatment of Psoriasis, Skin Disease Education Foundation, Las Vegas, 2010-2012.

Challenges in the Treatment of Psoriasis, American Academy of Dermatology, New Orleans, 2011

Treatment of Acne; an American Perspective, Mexican Dermatology Society, Mexico City, 2012, Brazilian Dermatology Society Sao Paulo, Brazil, 2012

What's New in Topical Therapy, American Academy of Dermatology, New Orleans, 2011

Topical Treatment of Psoriasis, Fall Clinical Dermatology Meeting, 2010

Topical Treatment of Psoriasis and Topical Treatment of Acne, Skin Disease Educational Foundation Meeting, Las Vegas, Nevada 2010

Update on the Treatment of Acne, The Philippine Dermatology Society, Manila, Philippines, November 2010.

What's New in the Treatment of Acne: An American Prospective, The Korean Society for Acne Research, Seoul, Korea March 2010.

Update on Acne Therapy, The Hong Kong Society of Dermatology and Venereology, Hong Kong, March 2010.

What's Hot in Topical Therapy of Atopic Dermatitis and Psoriasis? Fall Clinical Dermatology Meeting, Las Vegas, October 2009.

What's New in Acne Therapy? The Australasian College of Dermatologists, Broadbeach, Queensland, Australia, May 2009.

New Approaches to Topical Therapy for Psoriasis, Atlantic Dermatology Meeting, Quebec City, Canada, 2008.

What's Hot in Topical Therapy for Psoriasis, Latin American Dermatology Meeting, Curitiba, Brazil, 2008.

Treatment of Scalp Psoriasis, World Congress of Dermatology, Buenos Aires, Argentina. 2008.

Innovative Topical Therapy, Winter Clinical Dermatology Meeting, Maui, Hawaii, 2008.

Myths and Misconceptions of Topical Steroids. American Academy of Dermatology, San Francisco and Washington, DC. 2006, 2007.

What's New in Topical Therapy, American Academy of Dermatology, Washington, DC. 2007.

Non-Melanoma Skin Cancer, Genesys Regional Medical Center, CME meeting, 2005.

What's new in the topical treatment of Psoriasis, Hawaii Dermatology Meeting, 2005, 2004.

Topical Therapy for Psoriasis, American Academy of Dermatology Summer Meeting, Chicago. 2005.

Biologics for the Treatment of Psoriasis, Ohio Dermatology Society, 2004.

Dermatology for the OB-Gyn, State ACOG Meetings: Michigan, Indiana, Kansas. 2004.

What's Hot in Seborrheic Dermatitis, Skin Disease Education Foundation, Hawaii Dermatology Meeting. 2004.

Topical Therapy for Psoriasis, National Psoriasis Foundation Chief Residents Meeting, 2001 and 2002.

What's New in Androgenetic Alopecia, Internet lecture series, 2002.

Sun Damage and Skin Cancer, Medscape, CME internet lecture, 2000.

Treatment of Onychomycosis, Core facility, CME lecture, Henry Ford Hospital, 2000.

Physician Judge, Hats off Charity Challenge with Propecia, 1999-2000.

An Update on Foam Technology for the treatment of Psoriasis, Hawaii Dermatology Meeting, 1999 and 2000.

Long Term Results with Finasteride, Hawaii Dermatology Meeting, 2000.

Understanding Moles and Melanoma, Michigan Medical Society Meeting, 1998.

MEDIA

Local and National television and newspaper interviews.

BOARDS

National Psoriasis Foundation Medical Board, Acne and Rosacea Society Treasurer 2011-13.